PepGen (PEPG) announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are being offered by PepGen. PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes. Leerink Partners and Stifel are acting as joint book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEPG:
- PepGen says FREEDOM clinical study achieves all key objectives
- PepGen initiated with a Buy at Guggenheim ahead of DM1 data
- PepGen initiated with a Buy at Guggenheim
- PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating
- PepGen Inc. Reports Q2 2025 Financial Results